BridgeMD
IMpact of Phenylephrine vs. norAdrenaline on systemic hemodynamics and Cerebral Tissue circulation and oxygenation in anesthetized brain tumor patients (IMPACT)
EU CTIS ID: 2024-515400-40-00
What this study is testing
In the attempt to improve brain outcomes, we initiate this interdisciplinary and international collaborative project to understand the impact of two commonly used vasopressor agents (phenylephrine vs. noradrenaline) on cerebral circulation and oxygenation in patients undergoing brain tumor resection. We also aim to understand the impact of vasopressor-induced changes in systemic hemodynamics on regional perfusion in organs including the brain, heart and muscle.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Subjects aged 18-75 yr. scheduled for elective craniotomy for supratentorial tumors with a minimum size of 3 cm (measured as the largest diameter in any plane) are included
You likely can't join if
- Exclusion criteria are history of allergy or intolerance to one of the study medications, an American Society of Anesthesiologists (ASA) physical status IV to VI, pregnancy (positive pregnancy urine test) or breastfeeding and inability to give written informed consent
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.